×

Argos Therapeutics COO Fred Miesowicz to Join Panel Discussion on Manufacturing Challenges in Cell Therapy at the World Stem Cells and Regenerative Medicine Congress

Argos Therapeutics, Inc. logo

DURHAM, N.C., May 15, 2014 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS), a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis™ technology platform, today announced that company chief operating officer Fred Miesowicz, Ph.D., will participate in a panel discussion on manufacturing challenges in the development of cell therapies. The discussion, entitled "Having the Manufacturing Foresight to Prepare for Your Manufacturing Challenges During Clinical Development," will take place on Tuesday, May 20, 2014, during the 9th Annual World Stem Cells and Regenerative Medicine Congress in London.

Program: Panel discussion: "Having the Manufacturing Foresight to Prepare for Your Manufacturing Challenges During Clinical Development"
Date: Tuesday, May 20, 2014
Time: 15:00 GMT
Location: 155 Bishopsgate, London, UK EC2M 3Yd

About Argos Therapeutics

Argos Therapeutics is a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis™ technology platform. Argos' most advanced product candidate, AGS-003, is being evaluated in the pivotal ADAPT Phase 3 clinical trial for the treatment of metastatic renal cell carcinoma (mRCC). The company also plans to report data from its Phase 2b trial of AGS-004 for the treatment of HIV in mid-2014. For more information about Argos Therapeutics, visit www.argostherapeutics.com.

CONTACT: Media: David Salisbury Berry & Company Public Relations dsalisbury@berrypr.com (212) 253-8881 Investors: Angeli Kolhatkar Burns McClellan akolhatkar@burnsmc.com (212) 213-0006

Source:Argos Therapeutics, Inc.